CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end cash. Management ...
Recursion ended Q2 2025 with $533M in cash, a 35% reduction in expected cash burn by 2026 versus 2024, and reaffirmed guidance for over $100M in partnership inflows by end of 2026. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results